These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 33126570)

  • 1. The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs.
    Golay J; Taylor RP
    Antibodies (Basel); 2020 Oct; 9(4):. PubMed ID: 33126570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies.
    VanDerMeid KR; Elliott MR; Baran AM; Barr PM; Chu CC; Zent CS
    Cancer Immunol Res; 2018 Oct; 6(10):1150-1160. PubMed ID: 30089638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
    Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
    MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
    Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
    J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
    Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
    Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
    Braster R; O'Toole T; van Egmond M
    Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
    Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
    Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential influence on antibody dependent cellular phagocytosis by different glycoforms on therapeutic Monoclonal antibodies.
    Kuhns S; Shu J; Xiang C; Guzman R; Zhang Q; Bretzlaff W; Miscalichi N; Kalenian K; Joubert M
    J Biotechnol; 2020 Jun; 317():5-15. PubMed ID: 32361021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
    Masui H; Moroyama T; Mendelsohn J
    Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct targeting of cancer cells with antibodies: What can we learn from the successes and failure of unconjugated antibodies for lymphoid neoplasias?
    Golay J
    J Autoimmun; 2017 Dec; 85():6-19. PubMed ID: 28666691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner.
    Musich T; Li L; Liu L; Zolla-Pazner S; Robert-Guroff M; Gorny MK
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28122974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.
    Meyer S; Leusen JH; Boross P
    MAbs; 2014; 6(5):1133-44. PubMed ID: 25517299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
    Boyerinas B; Jochems C; Fantini M; Heery CR; Gulley JL; Tsang KY; Schlom J
    Cancer Immunol Res; 2015 Oct; 3(10):1148-1157. PubMed ID: 26014098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives.
    Lo Nigro C; Macagno M; Sangiolo D; Bertolaccini L; Aglietta M; Merlano MC
    Ann Transl Med; 2019 Mar; 7(5):105. PubMed ID: 31019955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
    Campbell KS; Cohen AD; Pazina T
    Front Immunol; 2018; 9():2551. PubMed ID: 30455698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer.
    Bakema JE; van Egmond M
    Curr Top Microbiol Immunol; 2014; 382():373-92. PubMed ID: 25116109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor targeting IgG3 triggers complement-mediated lysis of decay-accelerating factor expressing tumor cells through the alternative pathway amplification loop.
    Rösner T; Lohse S; Peipp M; Valerius T; Derer S
    J Immunol; 2014 Aug; 193(3):1485-95. PubMed ID: 24973443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
    Robak T; Robak E
    BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
    Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
    Front Immunol; 2018; 9():2873. PubMed ID: 30574146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.